Steglatro (ertugliflozin) / Pfizer, Merck (MSD) - LARVOL DELTA

Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database. (PubMed, Front Endocrinol (Lausanne)) - "We extracted adverse event (AE) reports from the FAERS database from the first quarter (Q1) of 2013 to the fourth quarter (Q4) of 2025 in which the combined regimen (ertugliflozin, dapagliflozin, empagliflozin, or canagliflozin plus metformin) was designated as the primary suspect. The predominance of hospitalisation-related events, coupled with the substantial concentration of AEs within the initial 30-day window, highlights the early treatment phase as a potentially critical monitoring period. These exploratory findings warrant rigorous validation through prospective cohort studies."

Adverse events • Journal • Acute Kidney Injury • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: a Bayesian network meta-analysis of randomized controlled trials (ESC 2026) - "Purpose: To rank the comparative efficacy of canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin versus placebo on all-cause mortality, cardiovascular mortality, and heart failure hospitalization in patients with HFmrEF/HFpEF. In this Bayesian network meta-analysis of HFmrEF/HFpEF trials, ertugliflozin ranked highest for prevention of heart failure hospitalization and cardiovascular mortality, while ipragliflozin showed the most favorable point estimate for all-cause mortality. However, wide credible intervals and sparse head-to-head data prevent firm conclusions on differential efficacy among SGLT2is. Large, adequately powered head-to-head randomized controlled trials are urgently needed to definitively establish whether meaningful differences exist among individual SGLT2 inhibitors in this population."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Fibrotic MASLD With Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Analysis of Hepatic and Mortality Outcomes (ACG 2026) - "Cohort 1 received GLP-1RAs (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide); Cohort 2 received SGLT-2is (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin)... Post-matching cohorts were balanced (47.4% female, ~69% White). New cirrhosis did not differ significantly (0.11% vs. 0.15%; RR 0.74, 95% CI 0.48â1.13; p=0.16)."

Clinical • Real-world • Real-world evidence • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Ertugliflozin reduces blood pressure and eGFR during both moderate- and high-sodium intake in people with type 2 diabetes (EASD 2026) - P4 | "ERTU has similar BP-lowering effects during MS and HS intake, suggesting its antihypertensive effect is independent of sodium intake."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmaceutical cocrystals beyond enteral drug delivery: from concept to translation. (PubMed, J Control Release) - "Over the past decade, significant research efforts have been dedicated to the development of oral cocrystal dosage forms, giving rise to the launch of groundbreaking medications such as Entresto® and Steglatro®. Finally, future perspectives will be provided to propose innovative approaches to close the knowledge gaps. We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions."

Journal • Review

Case Report: Efficacy and safety of SGLT2 inhibitors in patients with Alström syndrome: a follow-up report of two siblings from the same family. (PubMed, Front Endocrinol (Lausanne)) - "Ertugliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is approved for the glycemic management of patients with type 2 diabetes...The agent was generally well tolerated, with no serious adverse events reported. Owing to the inherent limitations of this analysis-including a small sample size (n = 2), absence of a control group, and lack of histopathological or mechanistic biomarker data-these observations remain preliminary and warrant validation in adequately powered, prospective, controlled clinical trials."

Clinical • Journal • Retrospective data • Alstrom Syndrome • Cardiomyopathy • Cardiovascular • Diabetes • Endocrine Disorders • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Ophthalmology • Otorhinolaryngology • Renal Disease • Type 2 Diabetes Mellitus

Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. (PubMed, Daru) - "SGLT2 inhibitors were not associated with a statistically significant increase in any UTI or serious/complicated UTI. These findings support a distinction between lower-grade urinary events and clinically severe urinary infection, and suggest that urinary safety concerns should not be considered equivalent to the established excess risk of external genital infection."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Urology

Comparative effects of SGLT2 inhibitors on Erythropoiesis: A systematic review and network meta-analysis. (PubMed, Diabetes Metab Syndr) - "SGLT2is consistently increase hemoglobin, hematocrit, RBC count, and erythropoietin, with intra-class differences observed for specific outcomes. However, low to very low certainty evidence precludes definitive comparative recommendations."

Journal • Retrospective data • Hematological Disorders

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Left Ventricular Global Longitudinal Strain in Adults with Type 2 Diabetes Mellitus: A Systematic Review. (PubMed, J Clin Med) - "The studies evaluated dapagliflozin, empagliflozin, ertugliflozin, canagliflozin, or mixed SGLT2i regimens across heterogeneous clinical populations, including patients with preserved ejection fraction, pre-heart failure, diabetes-related cardiomyopathy, chronic heart failure, coronary artery disease, hypertension, non-alcoholic fatty liver disease, and cardio-oncology risk. However, current evidence does not definitively establish a consistent treatment effect across all populations. Larger randomized controlled trials with standardized strain imaging protocols, predefined LV GLS endpoints, and clinically relevant follow-up are needed to determine whether SGLT2i-related improvements in LV GLS reflect true myocardial benefit and translate into improved cardiovascular outcomes."

Journal • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hepatology • Hypertension • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Type 2 Diabetes Mellitus

Sodium-glucose Cotransporter-2 Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis (ISTH 2026) - "Among individual agents, empagliflozin was associated with lower VTE risk (OR, 0.62 [95% CI: 0.58-0.90]), whereas estimates for dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin did not differ significantly from placebo. Additional studies are warranted to clarify which patient populations may derive the greatest benefit. Table or Figure Upload (1) Forest plot summarizing the association of SGLT2 inhibitors and overall total venous thromboembolism events Page 2 Table or Figure Upload (2) Forest plot summarizing the association of individual SGLT2 inhibitors and overall total venous thromboembolism events DOI*10.1016/j.rpth.2026.103717"

Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus • Venous Thromboembolism

Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin. (PubMed, PLoS One) - "Our findings highlight the importance of these drug interactions, which could inform dose adjustments to enhance safety in patients with T2DM and hypertension."

Journal • PK/PD data • Breast Cancer • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Effects of gliflozins on bone health of patients with chronic kidney disease: a systematic review. (PubMed, J Nephrol) - "Mostly, SGLT2i demonstrated a possible reassuring skeletal safety profile in CKD. Initial safety concerns regarding fractures have not been consistently supported, although evidence in moderate-to-advanced CKD remains limited. Long-term, prospectively defined skeletal outcomes are needed to confirm these findings and clarify class effects."

Journal • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

Inflammatory Biomarkers and Their Associations with Arrhythmic Burden Following SGLT2-I Treatment in Chronic Heart Failure-A Subanalysis of the ERASe Trial. (PubMed, J Clin Med) - " This pre-defined subanalysis investigated changes in pre-specified inflammatory biomarkers from baseline to week 52 in response to 5 mg Ertugliflozin compared to placebo and their associations to the incidence of VA burden...This may suggest a potential higher risk for VA in SGLT2-I-treated patients in the setting of heightened inflammatory activity. However, this finding is based on a single interaction analysis in a small sample size, and the results should therefore be considered exploratory and hypothesis-generating, and must be interpreted cautiously."

Biomarker • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • CRP • IL6

Assessing the Equitable Use of Formulary Drug Tier Systems: Consequences for Geriatric Patient Population Access and Accessible Medication. (PubMed, Innov Pharm) - "For example, Alzheimer's medications like galantamine and rivastigmine were found in higher tiers, leading to increased out-of-pocket expenses, while COPD treatments such as Symbicort and Trelegy Ellipta, although in preferred tiers, still imposed significant financial burdens. Rheumatoid arthritis drugs showed a wide cost range, with Humira in Tier 5 presenting the highest financial challenge. Similarly, ischemic heart disease and type 2 diabetes medications varied in affordability, with drugs like Eliquis and Steglatro positioned in higher tiers, significantly impacting patient costs and potential treatment adherence...The results highlight the pressing requirement for more effective policy actions that support price transparency, promote the utilization of cost-effective generics, and deter the unwarranted classification of generic drugs in higher formulary tiers."

Journal • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Coronary Artery Disease • Dementia • Diabetes • Geriatric Disorders • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

Ertugliflozin Reduces Blood Pressure and EGFR during Both Moderate- and High-Sodium Intake in People with Type 2 Diabetes. (ADA 2026) - "ERTU has similar BP-lowering effects during MS and HS intake, suggesting its antihypertensive effect is independent of sodium intake."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • EGFR

Ertugliflozin Mitigates Blood Pressure Increments during a High-Sodium Diet in People with Type 2 Diabetes (ADA 2026) - "ERTU prevented the BP-increment induced by HS intake without altering sodium excretion. Mitigation of sodium sensitivity by ERTU may contribute to its beneficial cardio-kidney effects."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction (clinicaltrials.gov) - P4 | N=476 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

New P4 trial • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. (PubMed, Drugs Context) - "In Europe, the four currently approved SGLT2is for the treatment of type 2 diabetes mellitus - dapagliflozin, empagliflozin, canagliflozin and ertugliflozin - all have demonstrated cardiovascular and renal benefits in large cardiovascular outcomes trials. Overall, SGLT2is have demonstrated consistent cardiovascular safety and clinically meaningful benefits in selected outcomes across CMR conditions, with variations amongst individual agents reflecting differences in trial populations, study design and approved indications. This review summarizes current evidence to support individualized therapeutic decision-making rather than comparative positioning within the class."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration. (PubMed, Vet Sci) - "It is proposed that a starting dose for ertugliflozin in horses be in the range 0.05-0.1 mg/kg. Further pharmacokinetic studies are required to optimise the dose regimen for treating horses with hyperinsulinaemia."

Journal • PK/PD data • Endocrine Disorders • Hematological Disorders • Metabolic Disorders

SGLT2i vs DPP-4i in Prostate Cancer Patients on Androgen Deprivation Therapy with Type 2 Diabetes Mellitus: A Propensity-Matched TriNetX Analysis (AUA 2026) - "Eligible patients were men (≥45 years) with T2DM who were on GnRH analogues (ADT) and initiated SGLT2i (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) or DPP-4i. In men with T2DM receiving ADT, initiation of SGLT2i was associated with significantly lower all-cause mortality, fewer major cardiovascular/cerebrovascular events, and reduced progression to kidney failure compared with DPP-4i in real-world practice. These data support considering SGLT2i as the preferred glucose-lowering therapy for ADT-treated men pending confirmation in randomized trials."

Clinical • Cerebral Hemorrhage • Chronic Kidney Disease • Diabetes • Genito-urinary Cancer • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Oncology • Prostate Cancer • Renal Disease • Solid Tumor • Subarachnoid Hemorrhage • Type 2 Diabetes Mellitus

Factors That Influence Blood Pressure Changes With the Use of Sodium-Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes. (PubMed, Pharmacotherapy) - "Blood pressure responses to SGLT2 inhibitors were driven by baseline blood pressure, with the greatest reductions observed in patients with elevated blood pressure at initiation. Individuals with lower starting pressures showed minimal change or slight increases, indicating a normalizing effect rather than uniform blood pressure lowering with initiation of SGLT2 inhibitors. These findings support incorporating baseline blood pressure into treatment selection to optimize cardiovascular risk management in patients with type 2 diabetes."

Journal • Retrospective data • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF (clinicaltrials.gov) - P4 | N=28 | Completed | Sponsor: Icahn School of Medicine at Mount Sinai | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin. (PubMed, Diabetes Res Clin Pract) - "In conclusion, bexagliflozin, ertugliflozin, and sotagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure. Bexagliflozin and sotagliflozin may offer additional benefits in preventing the risk of myocardial infarction."

Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus. (PubMed, J Am Coll Cardiol) - "In this large-scale real-world study, individual GLP-1RAs and SGLT2Is exhibited largely comparable cardiovascular benefits, including in patients with established CVD. These findings align with network meta-analytic estimates from major cardiovascular outcome trials and broadly support current treatment guidelines. Clinical choices should be guided by relevant factors such as safety, adherence, tolerability, cost, and patient preference, where further work is needed."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration. (PubMed, Domest Anim Endocrinol) - "It was hypothesised that oral ertugliflozin, administered before and after intra-articular (IA) triamcinolone acetonide (TA), will significantly lower the insulin response in comparison to placebo. There was a 99.13% probability that the ertugliflozin Cmax was lower than that for placebo. In conclusion, four once-daily doses of oral ertugliflozin (0.05 mg/kg) given prior to and again following IA TA administration, attenuated the rise in plasma insulin concentrations in non-insulin-dysregulated horses."

Journal • Metabolic Disorders